Loomis Sayles & Co. L P Cuts Stock Position in Insmed Incorporated (NASDAQ:INSM)

Loomis Sayles & Co. L P lowered its position in Insmed Incorporated (NASDAQ:INSM - Free Report) by 2.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,174,791 shares of the biopharmaceutical company's stock after selling 35,396 shares during the period. Loomis Sayles & Co. L P owned about 0.66% of Insmed worth $81,108,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of Insmed by 6.3% in the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock valued at $1,257,838,000 after buying an additional 1,075,796 shares during the period. Vestal Point Capital LP lifted its holdings in Insmed by 113.3% in the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company's stock valued at $116,800,000 after acquiring an additional 850,000 shares during the period. Artisan Partners Limited Partnership boosted its position in shares of Insmed by 8.4% during the 4th quarter. Artisan Partners Limited Partnership now owns 3,126,339 shares of the biopharmaceutical company's stock worth $215,842,000 after purchasing an additional 242,242 shares in the last quarter. Eventide Asset Management LLC grew its stake in shares of Insmed by 34.2% during the 3rd quarter. Eventide Asset Management LLC now owns 906,395 shares of the biopharmaceutical company's stock worth $66,167,000 after purchasing an additional 231,210 shares during the period. Finally, Principal Financial Group Inc. grew its stake in shares of Insmed by 12.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company's stock worth $136,648,000 after purchasing an additional 214,130 shares during the period.

Remove Ads

Analysts Set New Price Targets

A number of analysts recently commented on INSM shares. Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a report on Wednesday, February 19th. Truist Financial boosted their price target on Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. JPMorgan Chase & Co. lifted their price objective on Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a report on Friday, February 7th. UBS Group upped their target price on Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Finally, Guggenheim reaffirmed a "buy" rating and set a $101.00 price target on shares of Insmed in a research note on Tuesday, February 25th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $94.00.

Insider Buying and Selling

In other Insmed news, insider Martina M.D. Flammer sold 6,172 shares of the business's stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $63.64, for a total transaction of $392,786.08. Following the completion of the sale, the insider now owns 101,549 shares of the company's stock, valued at approximately $6,462,578.36. The trade was a 5.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the firm's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total value of $1,309,500.00. Following the completion of the transaction, the chief executive officer now owns 384,960 shares in the company, valued at approximately $26,885,606.40. This trade represents a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 550,957 shares of company stock valued at $42,992,528. Insiders own 4.60% of the company's stock.

Insmed Trading Down 3.0 %

Shares of Insmed stock traded down $2.36 during trading hours on Monday, reaching $75.63. 765,876 shares of the company's stock were exchanged, compared to its average volume of 2,225,323. The firm has a market capitalization of $13.69 billion, a price-to-earnings ratio of -13.54 and a beta of 1.28. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The company has a fifty day moving average of $78.18 and a 200-day moving average of $74.00.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The business had revenue of $104.44 million during the quarter, compared to analysts' expectations of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Sell-side analysts forecast that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.